Creative Biolabs has expanded its specialized antibody portfolio targeting structural and envelope proteins from HIV-1, HIV-2, and HTLV-1, a move that could accelerate research into human retroviruses. The new offerings include antibodies against key viral proteins such as gp140, gp36, and HTLV-1 gag p19, addressing a growing need for reagents that can distinguish specific viral components across different experimental formats.
Human retroviruses remain a critical area of study in virology, immunology, vaccine development, and diagnostic assay development. Research antibodies targeting defined viral proteins are essential for investigating viral entry, epitope recognition, immune responses, and assay development. Creative Biolabs’ expanded portfolio is designed specifically for research applications involving these three major retroviruses.
For HIV-1, the most prevalent strain of the human immunodeficiency virus, the viral envelope is a primary focus. The gp140 protein, an uncleaved ectodomain of the HIV-1 envelope glycoprotein, is a key target for broadly neutralizing antibodies and vaccine design. Creative Biolabs now offers an anti-gp140 HIV-1 antibody for research on HIV-1 envelope biology, antigen recognition, and related assay development.
HIV-2, while less common than HIV-1, presents unique clinical challenges due to its distinct genetic makeup and different disease progression rates. Because gp36 is an HIV-2 envelope-associated antigen, antibodies targeting gp36 can serve as useful tools for studying antigen recognition, cross-reactivity, and the development and evaluation of HIV-2-focused assay concepts.
Beyond HIV, the human T-cell lymphotropic virus type 1 (HTLV-1) is another significant retroviral threat, known to cause adult T-cell leukemia/lymphoma (ATL) and HTLV-1-associated myelopathy. The HTLV-1 gag p19 protein is a viral core protein commonly investigated in studies of HTLV-1 biology, viral protein expression, and immune recognition. Creative Biolabs’ anti-HTLV-1 gag p19 antibody is intended for research applications such as Western blot, ELISA, and immunohistochemistry, supporting investigations into HTLV-1 pathogenesis and related virology questions.
The expansion matters because retrovirus research often depends on reagents that can reliably distinguish specific viral proteins and perform across different experimental platforms. By broadening antibody coverage across HIV-1, HIV-2, and HTLV-1 targets, Creative Biolabs aims to give researchers more options for studying viral proteins, antigen recognition, and assay development. This could facilitate comparative studies, improve understanding of viral mechanisms, and aid in the design of better diagnostic and therapeutic strategies.
“Retrovirus research often depends on reagents that distinguish specific viral proteins and support different experimental formats,” said a senior scientist at Creative Biolabs. “By expanding antibody coverage across HIV-1, HIV-2, and HTLV-1 targets, we aim to give researchers additional options for studying viral proteins, antigen recognition, and assay development.”
Creative Biolabs provides retrovirus-targeted antibodies and custom antibody development services for research applications in virology and infectious disease. For more information about the complete range of retrovirus-targeted antibodies and custom services, visit https://www.antibody-creativebiolabs.com/.
The products are for research use only and are not intended for diagnostic or therapeutic procedures.
